Shanghai, July 4, 2024 – Luye Pharma Group announced that its Mimeixin (oxycodone hydrochloride and naloxone hydrochloride sustained-release tablets) was approved for marketing by China's Na...
The world’s first long-acting microsphere formulation for treating Parkinson’s disease is another CNS product of the company approved in the fast track processJune 20, 2024 – Luye Ph...
June 11, 2024 - Luye Pharma Group today announced that its second-generation long-acting injectable (LAI) antipsychotic Meibirui (Paliperidone Palmitate Injection) has been approved for marketing by C...
June 6, 2024 – Luye Pharma Group announced that its partner Towa Pharmaceutical Co., Ltd. (Towa) has filed a New Drug Application (NDA) to the Ministry of Health, Labour and Welfare (MHLW) in Ja...
Boan Biotech announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for its Dul...
Boan Biotech today announced that Boluojia®, a denosumab injection (120mg) developed by the company, has been approved for marketing by China’s National Medical Products Administration (NMPA) fo...
Boan Biotech (6955.HK) today announced its 2023 financial results and latest developments.High-quality development delivering remarkable performanceDuring the reporting period, the company's reven...
A symposium called the New Treatment Paradigm for Small Cell Lung Cancer (SCLC) organized by the Hong Kong Cancer Therapy Society (HKCTS) with support from Luye Pharma Group (Luye Pharma) took place i...
Boan Biotech announced today that it has received GMP certification from the Brazilian Agência Nacional de Vigilância Sanitária (ANVISA) for its biological product, Boyuno®(Bevacizu...
December 27, 2023 -- Boan Biotech today announced that two of its Claudin18.2-targeted investigational drugs have been granted the Orphan Drug Designation (ODD) for the treatment of pancreatic cancer ...
TOP